Vitae, Boehringer in AD deal
Vitae Pharmaceuticals Inc. (Fort Washington, Pa.) granted Boehringer Ingelheim GmbH (Ingelheim, Germany) exclusive, worldwide rights to develop and commercialize Vitae's beta-secretase inhibitor program. The inhibitors of beta-site APP-cleaving enzyme 1 (BACE1) are in lead optimization to treat Alzheimer's disease. Vitae will receive $42 million, which consists of an upfront payment, research funding and an equity investment. Vitae also is eligible for $200 million in milestones for the first compound developed, plus potential further milestones based on additional compounds, or other approved indications. Vitae is eligible for royalties. The companies will share responsibility for preclinical development, while Boehringer is responsible for clinical development. ...